Innate and adaptive arms of the immune system are in constant evolution during tumor development, progression, and following conventional cancer treatments (chemotherapy and radiation) or immune therapy.160 Targeting innate immune cells independently has shown promising results in both preclinical and clinical trials.79,90,92,94 Recently developed NK cell therapies have demonstrated significant tumor suppressive capabilities in preclinical studies.78,94 NK cells can be activated in the absence of MHC to recognize and target malignant cells. This evidence concerns the gene HLA-C and neoplasm.